|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:activeIn
|
Gram-positive bacteria
|
|
gptkbp:administeredBy
|
oral route
intravenous route
|
|
gptkbp:approvedBy
|
2000 (linezolid)
|
|
gptkbp:chemicalFormula
|
C3H7NO2 (core structure)
|
|
gptkbp:contains
|
one nitrogen atom
one oxygen atom
five-membered ring
oxazolidine ring
ketone group
one carbonyl group
|
|
gptkbp:developedBy
|
gptkb:Pharmacia_&_Upjohn
|
|
gptkbp:discoveredIn
|
1980s
|
|
gptkbp:example
|
gptkb:tedizolid
gptkb:eperezolid
gptkb:linezolid
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
oxazolidinones
|
|
gptkbp:inhibitedBy
|
bacterial ribosome
|
|
gptkbp:mechanismOfAction
|
protein synthesis inhibitor
|
|
gptkbp:notEffectiveAgainst
|
Gram-negative bacteria
|
|
gptkbp:resistantTo
|
mutation in 23S rRNA
|
|
gptkbp:sideEffect
|
gptkb:serotonin_syndrome
myelosuppression
|
|
gptkbp:subclassOf
|
heterocyclic compounds
|
|
gptkbp:usedAs
|
gptkb:antibiotic
|
|
gptkbp:usedFor
|
gptkb:pneumonia
gptkb:MRSA_infections
skin and soft tissue infections
VRE infections
|
|
gptkbp:bfsParent
|
gptkb:23S_rRNA
|
|
gptkbp:bfsLayer
|
6
|